ALT
Altimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.42
+5.88%Year over year
Reported trailing growth
- Revenue
- +55.0%
- EBITDA
- -5.2%
- EBIT
- -6.2%
- EPS
- +33.9%
- Free cash flow
- +6.2%
- Operating cash flow
- +6.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +10.4%
- EPS
- +17.2%
Three-year CAGR
- Revenue
- -69.0%
- EBITDA
- +8.2%
- EBIT
- +8.4%
- Net income
- +7.3%
- EPS
- +25.4%
- Free cash flow
- +15.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026